A promising new treatment for a common type of liver cancer has been given a special recognition in the UK, which could help speed up its development and make it available to patients sooner. BeOne Medicines, a company based in London, has been awarded an Innovation Passport for a drug called BGB‑B2033. This drug is a type of antibody designed to treat advanced or spreading hepatocellular carcinoma, a type of liver cancer that makes up 85% of all liver cancer cases. The recognition comes from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and allows the company to work closely with health authorities to move the treatment forward more quickly. The goal is to accelerate patient access to this investigational medicine. James Harris, the Interim General Manager of BeOne Medicines UK & Ireland, shared his excitement about the potential of BGB‑B2033. He explained that patients with this type of liver cancer often face a poor outlook, so new treatment options are desperately needed. BGB‑B2033 works by targeting two specific molecules: GPC3, a protein found in high amounts in liver cancer cells, and 4‑1BB, a receptor that helps boost the immune system’s response. The company plans to start a large global clinical trial by the end of 2026, which could lead to the drug being approved for wider use. In the US, BGB‑B2033 has already received fast-track status and orphan drug designation, which are special approvals to help develop treatments for serious conditions. In the UK, about 7,000 people are diagnosed with liver cancer each year, with most cases being hepatocellular carcinoma. Sadly, this type of cancer is often found at an advanced stage, and fewer than 15% of patients survive more than five years after diagnosis. The disease has also become more common in the past decade, increasing by nearly 25%.